Cantor Fitzgerald initiated coverage of Oric Pharmaceuticals with an Overweight rating and no price target. The company’s ORIC-114 is a differentiated brain penetrant exon 20 inhibitor in lung cancer that has a high probability of emerging as a best-in-class drug and entirely supports the stock’s current valuation, the analyst tells investors in a research note. The firm believes ORIC-944 offers an attractive risk/reward in the large prostate cancer market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ORIC:
- ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Oric Pharmaceuticals files to sell 12.5M shares of common stock for holders
